WebDoctor Encyclopedia

Central nervous system Childhood

Dysembryoplastic neuroepithelial tumour (DNET)

A dysembryoplastic neuroepithelial tumour (DNET) is a benign, slow-growing brain tumour of the cortex, usually in the temporal lobe. It mainly causes drug-resistant seizures starting in childhood or the teenage years, and surgery makes most people seizure-free.

Medically reviewed Last reviewed October 19, 2026

What is a dysembryoplastic neuroepithelial tumour?

A dysembryoplastic neuroepithelial tumour, usually shortened to DNET or DNT, is a benign, very slow-growing brain tumour. It forms in the cortex, the outer grey matter of the brain, most often in the temporal lobe.

The name reflects the idea that the tumour arises from cells that developed abnormally while the brain was forming (“dysembryoplastic”), and that it contains both nerve cells and supporting glial cells (“neuroepithelial”). It belongs to the group called glioneuronal tumours.

DNET is classed as a CNS WHO grade 1 tumour, the lowest grade. It almost never turns into a cancer, and it rarely grows much over the years.

The main problem it causes is epilepsy. Most people with DNET have focal seizures that began in childhood or adolescence, and these seizures often do not respond well to anti-seizure medicines. Surgery to remove the tumour stops seizures in most people (Bonney et al., 2016).

1. Key facts at a glance

Feature Details
Type of tumour Benign glioneuronal tumour of the cortex
WHO grade CNS WHO grade 1
How common Rare overall; one of the commonest tumours found in surgery for long-term epilepsy
Typical age Seizures usually start before age 20; diagnosis often in childhood or young adulthood
Sex Slightly more common in males
Usual site Temporal lobe, especially its inner part; also frontal and other lobes
Main symptom Focal seizures, often drug-resistant
Main treatment Surgical removal (epilepsy surgery)
Outlook Excellent survival; most people become seizure-free after complete removal

2. Causes and risk factors

The cause of DNET is not fully understood. It is not caused by head injury, infection, diet or lifestyle.

Gene changes

Gene change Notes
FGFR1 alterations Found in most DNETs; include duplication of part of the gene or small mutations that keep the FGFR1 growth signal switched on
Other MAPK pathway changes Occasionally, such as BRAF changes; BRAF V600E is less typical than in ganglioglioma
Brain development The tumour often sits in an area of abnormal cortex (cortical dysplasia)

These changes are acquired in the tumour and are not inherited. A small number of DNET-like tumours occur in people with neurofibromatosis type 1, but this link is uncommon.

Tumour Notes
DNET Cortical, bubbly appearance; FGFR1 changes
Ganglioglioma Cyst with a nodule; often BRAF V600E
Angiocentric glioma Rare; MYB changes
Polymorphous low-grade neuroepithelial tumour of the young (PLNTY) Calcified; BRAF or FGFR changes

These tumours are often grouped together as long-term epilepsy-associated tumours (LEATs).

3. How does it look

On MRI

Feature Description
Position In the cortex, extending a little into the white matter beneath
Shape Triangular or wedge-shaped, pointing inwards
Texture Multinodular, cyst-like or “bubbly”
Signal Very bright on T2-weighted images, dark on T1
FLAIR Often a bright rim around the bubbles
Mass effect Little or none; nearby structures are not pushed aside
Contrast enhancement Usually absent or faint
Skull Overlying bone may be thinned from long-standing pressure

During surgery

The tumour usually looks like soft, gelatinous, slightly swollen cortex. Its edges can be hard to see by eye, which is why surgeons use MRI guidance and sometimes brain recordings during the operation.

Under the microscope

Feature Description
Specific glioneuronal element Columns of small oligodendrocyte-like cells arranged along nerve fibres
Floating neurons Normal-looking nerve cells floating in pools of pale, mucoid fluid
Nodules Glial nodules in complex forms
Nearby cortex Often shows cortical dysplasia
Proliferation Very low Ki-67
Molecular FGFR1 alteration; no IDH mutation or 1p/19q codeletion

4. Symptoms

Seizures

Seizures are the main symptom and occur in almost everyone diagnosed with DNET. They are usually focal, meaning they start in one part of the brain.

Seizure type What it may look like
Focal aware seizure A strange rising feeling in the stomach, déjà vu, fear, an odd smell or taste
Focal impaired-awareness seizure Staring, not responding, lip-smacking, fumbling with the hands
Focal to bilateral tonic-clonic seizure Spreads to a convulsion with stiffening and jerking
Seizures with speech problems If the tumour is in a language area

Other symptoms

  • Memory problems, particularly with temporal lobe tumours
  • Learning or behaviour difficulties in some children, often related to frequent seizures
  • Tiredness after seizures or from medicines
  • Low mood or anxiety, common in long-standing epilepsy
  • Headache is uncommon, because the tumour rarely raises pressure in the head

What is unusual for DNET

Symptom Notes
Weakness of an arm or leg Rare; may suggest another diagnosis
Signs of raised pressure Such as vomiting and blurred vision; uncommon
Rapidly worsening symptoms Should prompt review of the diagnosis

When to seek medical advice

See a doctor after any first seizure, or if a child has episodes of staring, unresponsiveness or odd repetitive movements. Call emergency services if a seizure lasts more than 5 minutes, if seizures come one after another, or if the person is injured or does not recover.

5. Diagnosis

Test Purpose
Medical history and witness account Describes the seizures in detail
EEG (brain wave recording) Shows where seizures start
Video-EEG monitoring Records seizures on video and EEG, usually before surgery
MRI with epilepsy protocol Main test; shows the typical cortical, bubbly lesion
Neuropsychology assessment Measures memory, language and thinking before surgery
Functional MRI or Wada test Maps language and memory in some people
PET or SPECT scans Help locate the seizure focus if needed
Pathology after surgery Confirms the diagnosis and tests for FGFR1 changes

Conditions that can look similar

DNET can be confused with ganglioglioma, low-grade glioma, cortical dysplasia, cysts and oligodendroglioma. In children, a DNET can also be mistaken for other low-grade tumours with similar gene changes.

The epilepsy surgery assessment step by step

Step What happens
1. Referral To a specialist epilepsy centre, ideally soon after two medicines have failed
2. Video-EEG A stay of several days while seizures are recorded
3. Detailed MRI Confirms the lesion and its relation to important brain areas
4. Thinking and memory tests Set a baseline and predict the effect of surgery
5. Team meeting Specialists agree whether surgery is likely to help
6. Decision You or your family discuss benefits and risks before choosing

6. Treatment

Treatment is usually led by an epilepsy surgery team, including neurologists, neurosurgeons, neuropsychologists and radiologists.

Anti-seizure medicines

Medicines are the first treatment for seizures. However, many people with DNET continue to have seizures despite trying two or more medicines, which is called drug-resistant epilepsy.

Surgery

Approach Notes
Lesionectomy Removes the tumour itself
Extended lesionectomy Also removes nearby abnormal cortex that may generate seizures
Temporal lobe resection For tumours in the inner temporal lobe, may include the hippocampus
Awake surgery Used near language or movement areas
Intraoperative recording (ECoG) Helps identify seizure-producing tissue

Early surgery is increasingly recommended, because a shorter duration of epilepsy before surgery is linked with better seizure control and development. In a review of 29 studies, the median seizure-freedom rate after surgery was 86% (Bonney et al., 2016).

Other treatments

Option When it is used
MRI scans only Small tumours with well-controlled seizures
Laser ablation (LITT) A less invasive option in selected centres
Radiotherapy or chemotherapy Almost never needed
Targeted drugs (FGFR inhibitors) Experimental; considered only for rare growing tumours

Risks and side effects of surgery

Risk Notes
Memory or language changes Depends on side and site; assessed before surgery
Visual field loss Possible with temporal lobe surgery
Bleeding or infection Uncommon
Weakness Rare; depends on location
Low mood Can occur in recovery

What treatment involves day to day

Part of treatment What to expect
Pre-surgical tests Several weeks to months of assessment
Hospital stay Usually 3-7 days after surgery
Recovery Return to school or work often after 4-8 weeks
Medicines Usually continued for at least 1-2 years after surgery, then reduced gradually if seizure-free

DNET in children

Many people with DNET have their first seizure in childhood. Frequent seizures at a young age can interfere with learning, attention, memory and behaviour, and the side effects of several anti-seizure medicines add to the burden.

For this reason, paediatric epilepsy teams often recommend assessment for surgery soon after medicines have failed, rather than waiting for many years (Arfuso et al., 2024). After successful surgery, many children make progress at school and in their social lives, and some can stop their medicines altogether. Schools can help with individual education plans, extra time in exams and rest breaks.

7. Outlook (prognosis)

Measure Usual result
Survival Excellent; DNET is very rarely life-threatening
Seizure freedom after complete removal Around 8-9 in 10 people
Seizure freedom after partial removal Lower; some benefit from further surgery
Regrowth Uncommon after complete removal
Malignant change Extremely rare and reported only in isolated cases (Matsumura et al., 2020)

Long-term follow-up studies show that the tumour itself usually stays stable for decades, so the focus of care is the epilepsy rather than the tumour.

Children who become seizure-free often show improvements in learning, behaviour and quality of life. Some people can stop anti-seizure medicines completely after a period without seizures.

What affects the chance of becoming seizure-free?

Factor Effect
Complete removal of the tumour The most important factor for a good result
Removal of nearby abnormal cortex May further improve seizure control in some people
Shorter epilepsy duration before surgery Linked with better outcomes
Clear match between MRI and EEG findings Makes successful surgery more likely

8. Follow-up

Follow-up Purpose
Clinic review with the epilepsy team Monitor seizures and medicines
MRI at intervals Confirm complete removal and detect regrowth
Neuropsychology review Track memory, learning and mood
Medicine reduction plan Decide when and how to stop medicines safely

9. Living with DNET

  • Keep a seizure diary to share with your team, noting the date, time, what happened and any possible triggers
  • Take medicines regularly and do not stop them without advice
  • Follow seizure safety advice, such as showers instead of baths and care near water or heights
  • Check the driving rules that apply after seizures and after surgery
  • Ask for school support for children with learning or memory difficulties
  • Look after mood and sleep, as both affect seizure control; tiredness, stress and alcohol are common seizure triggers
  • Seek support from epilepsy and brain tumour charities

10. Frequently asked questions

Question Answer
Is DNET a cancer? No. It is a benign, grade 1 tumour
Will it spread? No; it stays where it started
Is it inherited? No
Will surgery cure my epilepsy? Most people become seizure-free, especially after complete removal
Do I need chemotherapy or radiotherapy? Almost never
Can I come off my medicines? Many people can, after a long seizure-free period and with medical advice

11. Questions to ask your care team

  • How sure are you that this is a DNET?
  • Are my seizures drug-resistant, and should I be assessed for surgery?
  • What are the risks to my memory, language or vision?
  • How likely am I to become seizure-free?
  • How long will I need anti-seizure medicines?
  • What does this mean for driving, school or work?

Resources

  1. Arfuso, M. et al. (2024) ‘Pediatric neuroglial tumors: a review of ependymoma and dysembryoplastic neuroepithelial tumor’, Pediatric Neurology, 156, pp. 139-146.
  2. Bonney, P.A. et al. (2016) ‘Review of seizure outcomes after surgical resection of dysembryoplastic neuroepithelial tumors’, Journal of Neuro-Oncology, 126(1), pp. 1-10.
  3. Chang, E.F. et al. (2010) ‘Seizure control outcomes after resection of dysembryoplastic neuroepithelial tumor in 50 patients’, Journal of Neurosurgery: Pediatrics, 5(1), pp. 123-130.
  4. Matsumura, N. et al. (2020) ‘Malignant transformation of a dysembryoplastic neuroepithelial tumor verified by a shared copy number gain of the tyrosine kinase domain of FGFR1’, Brain Tumor Pathology, 37(2), pp. 69-75.
  5. Wang, J. et al. (2022) ‘Preoperative MRI for postoperative seizure prediction: a radiomics study of dysembryoplastic neuroepithelial tumor and a systematic review’, Neurosurgical Focus, 53(4), E7.
  6. National Cancer Institute (2026) Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/child-astrocytoma-glioma-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.